Neuren Pharmaceuticals Future Growth
Future criteria checks 0/6
Neuren Pharmaceuticals's earnings are forecast to decline at 9.9% per annum while its annual revenue is expected to grow at 4.2% per year. EPS is expected to decline by 14.1% per annum. Return on equity is forecast to be 19% in 3 years.
Key information
-9.9%
Earnings growth rate
-14.1%
EPS growth rate
| Pharmaceuticals earnings growth | 37.1% |
| Revenue growth rate | 4.2% |
| Future return on equity | 19.0% |
| Analyst coverage | Good |
| Last updated | 18 Nov 2024 |
Recent future growth updates
Recent updates
New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)
Nov 11
Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up
Nov 08Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)
Oct 24Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models
Aug 29Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now
Aug 14Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today
May 31Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely
May 03An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued
Apr 01Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically
Mar 05Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors
Mar 02Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors
Dec 18Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues
Sep 02Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)
Aug 31This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year
Mar 03Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business
Jan 07We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
Sep 06Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth
May 31We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn
Feb 03Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation
Aug 06We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
May 05Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)
Feb 19Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?
Jan 04
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 240 | 109 | 103 | 88 | 4 |
| 12/31/2025 | 121 | 58 | 115 | 87 | 5 |
| 12/31/2024 | 189 | 113 | 36 | 69 | 4 |
| 6/30/2024 | 193 | 117 | 119 | 120 | N/A |
| 3/31/2024 | 213 | 137 | 152 | 152 | N/A |
| 12/31/2023 | 232 | 157 | 185 | 185 | N/A |
| 9/30/2023 | 155 | 106 | 120 | 120 | N/A |
| 6/30/2023 | 78 | 55 | 54 | 54 | N/A |
| 3/31/2023 | 47 | 28 | 29 | 29 | N/A |
| 12/31/2022 | 15 | 0 | 4 | 4 | N/A |
| 9/30/2022 | 9 | -3 | -3 | -3 | N/A |
| 6/30/2022 | 3 | -7 | -10 | -10 | N/A |
| 3/31/2022 | 3 | -7 | -10 | -10 | N/A |
| 12/31/2021 | 3 | -8 | -10 | -10 | N/A |
| 9/30/2021 | 2 | -10 | -10 | -10 | N/A |
| 6/30/2021 | 1 | -12 | -9 | -9 | N/A |
| 3/31/2021 | 1 | -11 | -9 | -9 | N/A |
| 12/31/2020 | 1 | -9 | -8 | -8 | N/A |
| 9/30/2020 | 1 | -8 | -9 | -9 | N/A |
| 6/30/2020 | 0 | -8 | -9 | -9 | N/A |
| 3/31/2020 | 0 | -9 | -10 | -10 | N/A |
| 12/31/2019 | 0 | -11 | -12 | -12 | N/A |
| 9/30/2019 | 7 | -6 | -5 | -5 | N/A |
| 6/30/2019 | 14 | -1 | 2 | 2 | N/A |
| 3/31/2019 | 14 | 1 | 4 | 4 | N/A |
| 12/31/2018 | 14 | 3 | 6 | 6 | N/A |
| 9/30/2018 | 7 | 3 | 0 | 0 | N/A |
| 6/30/2018 | 1 | 3 | -6 | -6 | N/A |
| 3/31/2018 | 1 | 3 | N/A | -6 | N/A |
| 12/31/2017 | 1 | 3 | N/A | -6 | N/A |
| 9/30/2017 | 2 | -2 | N/A | -7 | N/A |
| 6/30/2017 | 3 | -8 | N/A | -8 | N/A |
| 3/31/2017 | 3 | -10 | N/A | -10 | N/A |
| 12/31/2016 | 3 | -12 | N/A | -12 | N/A |
| 9/30/2016 | 2 | -14 | N/A | -14 | N/A |
| 6/30/2016 | 0 | -15 | N/A | -17 | N/A |
| 3/31/2016 | 1 | -14 | N/A | -15 | N/A |
| 12/31/2015 | 2 | -13 | N/A | -13 | N/A |
| 9/30/2015 | 2 | -11 | N/A | -11 | N/A |
| 6/30/2015 | 3 | -9 | N/A | -8 | N/A |
| 3/31/2015 | 3 | -9 | N/A | -7 | N/A |
| 12/31/2014 | 3 | -8 | N/A | -6 | N/A |
| 9/30/2014 | 3 | -10 | N/A | -7 | N/A |
| 6/30/2014 | 3 | -12 | N/A | -7 | N/A |
| 3/31/2014 | 4 | -11 | N/A | -7 | N/A |
| 12/31/2013 | 5 | -10 | N/A | -7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NEU's earnings are forecast to decline over the next 3 years (-9.9% per year).
Earnings vs Market: NEU's earnings are forecast to decline over the next 3 years (-9.9% per year).
High Growth Earnings: NEU's earnings are forecast to decline over the next 3 years.
Revenue vs Market: NEU's revenue (4.2% per year) is forecast to grow slower than the Australian market (5.9% per year).
High Growth Revenue: NEU's revenue (4.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NEU's Return on Equity is forecast to be low in 3 years time (19%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 16:51 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Neuren Pharmaceuticals Limited is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Russell Wright | Barclay Pearce Capital Pty Limited |
| Thomas Wakim | Bell Potter |
| Tara Speranza | Bell Potter |